Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma

Journal of Asthma

Volumn 44, Issue 3, 2007, Pages 195-196

  Liebhaber, Myron ^a   Dyer, Zeb ^a  

^a Sansum Clinic   (United States)

Author keywords

Allergic asthma; Anaphylaxis; Immunoglobulin E; Moderate to severe asthma; Omalizumab

Indexed keywords

ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HOME CARE; HUMAN; IMMUNOTHERAPY; MALE; STEROID THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; FEMALE; HOME CARE SERVICES; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34247157806     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701209749     Document Type: Article

References (14)

1. Burrows B, Martinez FD, Holonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271-277.
2. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewett CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-1071.
3. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996; 183:1303-1310.
4. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164:S1-S5.
5. Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB Jr, Cockcroft DW. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835-1840.
6. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Mathews J, Busse WW, Hogate ST, Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593.
7. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhumba-E25 Study Group. N Engl J Med 1999; 341:1966-1973.
8. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
9. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-942.
10. Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006; 117:759-766.
11. Xolair (omalizumab) [package insert]. East Hanover, NJ: Novartis; 2003.
12. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005; 29:31-48.
13. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2004; 3:CD003559.
14. Asthma in America: A landmark survey. 1998. Executive Summary. www.asthmainamerica.com/aaa index.html. Accessed August 1, 2006.